Nilotinib - CAS# 641571-10-0 ndopril RO-3306 downregulated expression of the

RO-3306 downregulated expression of the antiapoptotic proteins Bcl-2 and survivin and blocked p53-mediated induction of p21 and MDM2

DO3A-t-Bu-ester

InChiKey: UGJMXCAKCUNAIE-UHFFFAOYSA-N

and a α10 nAChR antagonist found in Panax

ABT-199’s cell-killing effect is selective and mechanism dependent

Nilotinib - CAS# 641571-10-0 ndopril RO-3306 downregulated expression of theNilotinib, also known as AMN107, is a small molecule tyrosine kinase inhibitor approved for the treatment of imatinib resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr Abl kinase inhibitor that is 10 30 fold more potent than imatinib in inhibiting Bcr Abl tyrosine kinase activity and